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BACKGROUND: Apical Membrane antigen 1 (AMA-1) is an 
important membrane protein that presents in all Plasmodium 
species and participates in critical phases in the attraction of cells.  
In human, it is one of the most immunodominant antigens with a 
protective immune response simulation role Apical Membrane 
antigen 1 (AMA-1) is an important membrane protein which 
presents in all Plasmodium species and is located on the surface of 
merozoite and sporozoites that participates in critical phases in 
attraction of human red blood cells by merozoites and hepatocytes 
by sporozoites, so in human, it is one of the most immunodominant 
antigens with a protective immune response simulation role. Since 
extra information is necessary to lighten of AMA-1 scope, we 
equaled genetic variation in P.vivax AMA-1 from 40 Iranian 
isolates with those reported from the other malarious countries. 
METHODS: Blood samples were collected from 40 patients’ 
positive of P.vivax, and genomic DNA was extracted from the 
blood. The nucleotide sequence for 446 amino acid (AA) residues 
(42–488 of PvAMA-1) of AMA-1 gene was amplified via PCR and 
then sequenced. 
RESULTS: A total of 24 different haplotypes were recognized 
between samples. No new haplotype was determined in this 
research that was reported previously in other regions of Iran and 
the world. We detected 37-point mutations at the nucleotide level in 
their sequences and showed 43 amino acid variations, at 37 
positions in which 6 sites demonstrate trimorphic polymorphism, 
and the others were dimorphic. 
CONCLUSION: Sequence analysis of the major haplotype showed 
95% similarity with P.vivax Sal-1 AMA-1 gene and high level of 
allelic diversity at the domain I of PvAMA-1 among P. vivax 
isolates of Iran. Because PvAMA-1 is noticeable as vaccine 
candidate antigen, these documents provide valuable information 
for the development of malaria vaccine. 
KEYWORDS: Plasmodium vivax, PvAMA-1, Iran, Genetic 
variation, Sistan  
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Malaria is a major public health problem in 
Middle East and tropical countries. Iran is 
located in the Middle East Region with low 
endemicity for malaria that occurs in south and 
southeast provinces in Iran (Hormozgan 
andSistan-Baluchistan). Both indigenous and 
imported malaria were described in these 
regions (1,2). Commonly, infection with P. 
vivax occurs in these areas in 90% of cases (3,4). 
More than 40% of people around the world are 
in danger of exposure to malaria. Approximately 
250 million clinical cases and 6000 deaths due 
to malaria are reported every year worldwide. 
Though most of these deaths are related to P. 
falciparum , P. vivax has the main load of the 
disease because of its complications like anemia, 
respiratory distress, coma, and even death.(5). 
In spite of combined therapies against 
malaria, It is important that studies be done to 
make the right vaccine. (6). 
Plasmodium species pass their life cycle by 
infecting host RBC and cause disease. This 
parasite causes contamination of the host cells 
by the production of protein antigens (7), and it 
seems Apical Membrane Antigen 1  (AMA-1) 
has the main role in this process (8,9). AMA-1 is 
a type 1 membrane integral protein, the 
extracellular portion of it has three major 
domains with eight intramolecular di-sulfide- 
bonds (10-12). Although the biological activity 
of AMA-1 is unknown, several studies have 
confirmed its role in binding to the host's red 
blood cells (13). Antibodies against AMA-1 can 
prevent infection of host RBC by P. falciparum 
species. Due to the commonality of AMA-1 
between P. falciparum and P. vivax, we can 
consider this antigen as the most important 
factor for developing a good vaccine against 
malaria species (14,15). 
One of the serious barriers in the way of 
developing vaccine against malaria is the high 
genetic diversity (16). In a study in Mali, 
provided vaccine was effective against one 
species of P.falciparum only (17), and in another 
study, the bivalent vaccine provided no 
protection (18). At the moment, multivalent 
vaccines also have a high risk of immune cross-
reactions (19,20). All these reasons represent 
that the genetic diversity of AMA-1 allele and 
indicate the P.vivax has more diversity than P. 
falciparum. The studies have shown that due to 
the biological differences between P. falciparum 
and P. vivax species, we cannot generalize the 
results of a species to another species (21,22).  
As a result, sequencing and understanding 
of the AMA-1 gene sequence in P.vivax will be 
necessary independently in endemic areas that 
are aimed at eradicating both species in order to 
develop the appropriate vaccine (23). In the 
recent research, the PvAMA-1 was sequenced 
and then compared with similar genes and tried 
to compare the mutations related to each AMA-1 
domain of I, II and III, with each other carefully. 
 
METHODS AND MATERIALS  
 
Study areas and blood samples collection: 
Giemsa stained thick and thin blood smears were 
collected from 40 referred confirmed patients 
positive of P. vivax by light microscopic 
analysis from healthcare centers in the study 
regions (Sistan-Bluchestan Province) to Zahedan 
Health Centers. After earning consent, the 
samples transformed to parasitology lab until 
DNA extraction.  
 
DNA extraction and PCR amplification: DNA 
was extracted by DynaBio Blood/Tissue 
Genomic DNA extraction kit (TAKAPUZIST®) 
according to manual.  The quantity and quality 
of extracted product was tested via 
spectrophotometer at 260 and 280 nm and 
electrophoresis on 1% agarose gel. The 
PvAMA-1 gene, including domain I, domain II 
and domain III, expressing amino acids (AA) 
from 42–488 was aimed for amplification. The 
primers were selected based on the sequence of 
P. vivax Sal-1 PvAMA-1gene (ACCESSION 
NO.: XM_001615397). The amplification for 
PCR was performed in a 200 µl PCR tube 
containing: 200 ng (2 µl) extracted DNA as 
template, 25 pmol(1 µl) of each primer, 7.5 µl of 
PCR master mix (Roche) and ddH2O up to 15 
µl. The targeted gene was amplified for 30 
cycles as follows: initial denaturation at 95°C 
for 5 min followed by 30 cycles with 
denaturation at 94 °C for for 20s, annealing at 
58◦C for 30s and extension at 72 °C for 2 min 
and final extension at 72 °C for 5 min), PCR 
product was 1330 bp (Figure 1) which contained 
domain I, domain II and domain III of the 
PvAMA-1 gene with PvAMA F (5′-
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CCATGGGGCCTACCGTTGAGAGAA-3′) and 
PvAMA R as (5′- 
CTCGAGTCATAGTAGCATCTGCTTGTT-3′) 
primers (24). The product was analyzed on 1% 
agarose gel against size marker (Fermentase®). 
 
Sequence analysis: Received sequencing results 
along with the chromatogram from Bioneer 
(Korea) check and were ordered by software 
Geneious. Nucleotide sequences were analyzed 
by Chromas 2.2 software and aligned by 
ClustalW program. The 40 Iranian sequences 
were compared with formerly consigned P. 
vivax AMA-1 in the GenBank. The nucleotide 
diversity and number of polymorphic sites (S), 
as well as the number of haplotypes (H) were 
obtained by DNASP software. Nucleotide 
variation and statistical analysis were 
investigated by MEGA software.  
AMA-1 gene of P. vivax Sal1 strain 
(Accession No. XM_001615397), as complete 
sequence, was used to find nucleotide and amino 
acid position numbers. The Plasmodium 
falciparum (Accession No.X86099) was used as 
an outgroup species to analyze impartiality tests. 
Maximum Likelihood (ML) algorithm using 
MEGA7 software. All characters were run 
unordered and equally weighted. Alignment 
gaps were treated as missing data. Bootstrap 
analysis was conducted using 1000 replicates. 
 
Ethical considerations: The experimental 
procedure was approved by the Committee of 
the Ethics on Zahedan University of Medical 
Sciences and performed in Infectious Diseases 




A total of 40 isolate sequences of the AMA- 1 
gene was identified from patients confirmed by 
blood smear. The 1330 bp in length, belonging 
to domains I, II and III (respectively to 1-615, 
616- 1029 and 1030-1338 bp region of AMA-1 
gene of Sal1 accession number: 
XM_001615397) was amplified by molecular 
methods (PCR) and sequenced among the 
Iranian Southeastern P.vivax isolates. There 
clearly was no recognized size polymorphism in 
PCR and all isolates exhibited in gel 
electrophoresis 1400 bp fragments 
approximately. Totally, 24 various haplotypes 
distinguished among 40 sequences (Figure 1). 
No new haplotypes were determined to 
cooperation with others haplotypes that were 
described previously in different loci of the 
world. Haplotypes 1, 2 with 4 copies and 
haplotype 5 with 5 copies demonstrated the most 
frequency, although the other 21 haplotypes 



















Figure 1: PCR electrophoresis on gel agarose: positive control (1), positive samples (2-5), negative 
control (6), size marker 1000 bp (7) 
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Figure 2: Single nucleotide polymorphisms (SNP) in Iranian isolates compared to Sal-1 isolate 
 
Totally, we observed 24, 8 and 5-point 
mutations at the nucleotide level in the analyzed 
sequences in Dom I, II and III respectively.  
In between, 1336 bp analyzed sequences the 37 
variable (polymorphic) nucleotide sites were 
demonstrated that 16 sites of them are singleton 
and 21 sites were multiplex 
 Among 37 variable nucleotides positions, six 
sites were trimorphic (3, 2 and 1 sites on Dom I, 
II and III respectively),  the others of variable 
nucleotides positions were dimorphic. 
Nucleotide diversity and haplotypes of the 
sequenced PvAMA-1 are demonstrated in Figure 
2. Sequences analyses showed 43 amino acid 
changes at 37 positions in which 6 sites (2, 3 and 
1 sites on Dom I, II and III respectively) 
demonstrated trimorphic polymorphism, and the 
others were dimorphic (Figure 3). Also, 
phylogenic tree conducted by neighbor-joining 
(NJ) using MEGA 6.0 based on AMA-1 
haplotypes is shown in Figure 4. The haplotypes 
of this research (H1–H24) and a Strain of P. 
vivax Sal1 (Accession No. XM_001615397), 
and four isolates from several countries were 
used in phylogenetic construction, containing S3 
EF025195: India, SKO814: Korea, EU395598: 
Indonesia. The sequence of AMA-1 in P. 
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Figure 3: The amino acid changes compared to Sal-1 isolate referred to PvAMA-1 gene  
 
Figure 4: Neighbor-Joining tree of the AMA-1 haplotypes using of MEGA 7. Bootstrap values based on to 1000 
replications. The haplotypes of this research (H1–H24) and a Strain of P. vivax Sal1 (Accession No. 
XM_001615397), and four isolates from several countries were used in phylogenetic construction, containing S3 
EF025195: India, SKO814: Korea, EU395598: Indonesia. The sequence of AMA-1 in P. falciparum (Accession 
No.X86099) used as an outgroup 
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Infectious and zoonotic diseases have a great 
importance in the Middle East and Africa 
(25,26). Although the Plasmodium vivax is 
mostly benign, due to its geographical extent, it 
causes significant socio-economic burdens in 
endemic areas. P. vivax is chronic malaria and 
causing frequent relapse in people. In addition, it 
affects the working capacity of people in the 
community. The reason for the limitation in the 
study of parasitic diseases, especially P. vivax, is 
related to the lack of proper culture and 
obtaining appropriate and sufficient antigens, 
severe symptoms of the disease, including 
anemia.. 
This species is responsible for 80 million 
malaria infections every year in the world. Due 
to its different variants, the detection of parasite 
genome for vaccine, diagnostic kits, drug 
therapy and subsequently control of the disease 
are essential.. 
AMA-1 is a member of a group of 
molecules that have been completely preserved 
in Plasmodium species (30), and it is expressed 
in the large scale on the surface of the merozoite 
of all species of Plasmodium and in the 
micronemes of them. This antigen plays a 
unique role, during the vital stages of the 
invasion of sporozoite cells into the liver and 
merozoite into red blood cells (31). The number 
of haplotypes is limited and exposes a limited 
diversity in each geographic region. In this 
study, 40 sequenced isolates from endemic 
malaria areas in a one-year period were analyzed 
and compared with deposited P. vivax AMA-1 
in the GenBank from malaria countries in Asia 
In the target gene, the region of this study is 
1338 bp, and the translated protein sequence 
contains 446 amino acids, which have 16 
cysteine sites. Using Blast and ClustalW 
software, dominant haplotype compared to 
previously deposited P. vivax AMA-1 in the 
GenBank database, which showed the highest 
homology with Indonesian isolates with a 
similarity of 99%. The analysis of nucleotides in 
comparison to this isolate led to a change in the 
9 amino acids. In the dominant haplotype 
changes on amino acid level were 11 cases 
which it was the least homology with Korea 
isolates. At the level of amino acids, most of 
these differences are observed in the DomI. In 
Iranian isolates, the Dom II with 3 amino acids 
was completely different from the Sal-1 isolate 
and these changes lead to the diversity of 
parasitic populations in different geographic 
regions. The dominant Iranian haplotype in the 
Dom II on 327 amino acid position (980 
nucleotide position) was different with all strains 
and could be considered as an indicator in the 
detection of Iranian isolates. In our study, Dom 
II was high difference with the previous reports 
of malaria. The Dom I and II are able to provide 
protection to the person therefore these markers 
are useful for assessing the presence of 
antimalarial antibodies in people living in 
endemic areas. This area can be a good 
candidate for immunological studies as well as a 
component in the provision of a proactive 
vaccine. The dominant Iranian haplotype at the 
level of amino acids, the least of these 
differences were in the Dom III with 1 
difference compared to the Sal-1 isolate. This 
domain is responsible for cross-reactivity 
between species. 
According to previous studies, the building 
of PvAMA-1 by 16 cysteine sites and the 
creation of disulfide bonds is stabilized. 
Cysteines are essential to stabilization of 
produced protein formation and specific 
antibodies against this protein.  
A similar study was conducted in Brazil 
and studied the variation of PvAMA-1 in 
northern Brazil. The number of tested samples in 
this study was 20, with more than 93% identity. 
In this study, 40 samples were examined and 
90% of the homology was observed (32). 
The only study in Iran was conducted by 
Motevalli Haghi that studied the variation of 
PvAMA-1 in southern Iran. The number of 
samples tested in this study was 6, with more 
than 94% identity. In this study, samples were 
examined and 90% of the homology was 
observed (24). 
The other study was conducted in Honduras 
with  85 cases and identified the genetic 
variation of PvAMA-1 genes which were a 
length of 466 nucleotides and encoded 151-154 
amino acids (33). 
Also, a study from Sri Lanka had shown the genetic 
diversity in Dom II of PvAMA-1 and confirm 11 
variations in the amino acid position as well as 21 
haplotypes with 9 distinct haplotypes in the PvAMA-
II gene (34). 
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In a study from South Korea, 30 haplotypes of P. 
vivax were identified, while the DOM II was most 
protected and the Dom I and III  had the highest 
mutations. In a study in South Korea, 66 samples of 
blood from infected with P.vivax, 30 haplotypes were 
identified from seven different cluster isolates while 
the DOM II was most protected and the Dom I and 
III  had the highest mutations (35). 
In conclusion, since the AMA-1 recombinant 
protein is a hopeful candidate for development of 
vaccine, applying it into polyvalent vaccine as a 
particular member might generate immune reactions 
more effective against parasites. Thus, this research 
along with previous research on the PvAMA-1 locus 
on the basis of the local recognition of AMA-1 
sequences could be so effective in guarding against 
P. vivax in malarious regions of Iran. In conclusion, 
we analyzed the genetic diversity of PvAMA-1 
between Iranian isolates. Our data indicate 
moderately high level of nucleotides and haplotype 
diversity at the PvAMA-1 between P. vivax isolates 
of Iran. Since PvAMA-1 is considered as vaccine 
candidate antigen, these data are valuable for the 




1. Heidari A, Keshavarz H, Shojaee S, Raeisi A, 
Dittrich S. In vivo susceptibility of Plasmodium 
vivax to chloroquine in Southeastern Iran. 
Iranian Journal of Parasitology. 2012;7(2):8. 
2. Mirahmadi H, Spotin A, Fallahi S, Taghipour 
N, Turki H, Tabaei SJS. Cloning and sequence 
analysis of recombinant plasmodium vivax 
merozoite surface protein 1 (PvMSP-142 kDa) 
in pTZ57R/T vector. Iranian Journal of 
Parasitology. 2015;10(2):197. 
3. Mardani A, Keshavarz H, Heidari A, Hajjaran 
H, Raeisi A, Khorramizadeh MR. Genetic 
diversity and natural selection at the domain I of 
apical membrane antigen-1 (AMA-1) of 
Plasmodium falciparum in isolates from Iran. 
Experimental parasitology. 2012;130(4):456. 
4. Ebrahimzadeh A, Dalir SN, Mirahmadi H, 
Mehravaran A, Khorashad AS, Turki H. The 
Incidence of Current Infection with Different 
Human Malaria Species by Polymerase Chain 
Reaction for Diagnosis of Suspicious Malaria 
Patients on Elimination Region Sistan and 
Baluchistan Province, Southeast of Iran. 
Jundishapur Journal of Microbiology. 
2017;10(10). 
5. White N, Dondorp A, Faiz A, Mishra S, Hien T. 
New global estimates of malaria deaths. The 
Lancet. 2012;380(9841):559-60. 
6. Duffy PE, Sibley CH. Are we losing artemisinin 
combination therapy already? The Lancet. 
2005;366(9501):1908-9. 
7. Treeck M, Zacherl S, Herrmann S, Cabrera A, 
Kono M, Struck NS, et al. Functional analysis 
of the leading malaria vaccine candidate AMA-
1 reveals an essential role for the cytoplasmic 
domain in the invasion process. PLoS 
pathogens. 2009;5(3):e1000322. 
8. Hehl AB, Lekutis C, Grigg ME, Bradley PJ, 
Dubremetz J-F, Ortega-Barria E, et al. 
Toxoplasma gondii Homologue of Plasmodium 
Apical Membrane Antigen 1 Is Involved in 
Invasion of Host Cells. Infection and immunity. 
2000;68(12):7078-86. 
9. Raeghi S, Sedeghi S, Sedeghi S. Prevalence of 
Toxoplasma gondii antibodies in cats in Urmia, 
northwest of Iran. Journal of Animal and Plant 
Science. 2011;21:132-4. 
10. Feng ZP, Keizer DW, Stevenson RA, Yao S, 
Babon JJ, Murphy VJ, et al. Structure and inter-
domain interactions of domain II from the 
blood-stage malarial protein, apical membrane 
antigen 1. Journal of molecular biology. 
2005;350(4):641-56. 
11. Remarque EJ, Faber BW, Kocken CH, Thomas 
AW. Apical membrane antigen 1: a malaria 
vaccine candidate in review. Trends Parasitol. 
2008;24(2):74-84. 
12. Mirahmadi H, Fallahi S, Tabaei SJS. Soluble 
recombinant merozoite surface antigen-142 kDa 
of Plasmodium vivax: an improved diagnostic 
antigen for vivax malaria. Journal of 
microbiological methods. 2016;123:44-50. 
13. Kato K, Mayer DG, Singh S, Reid M, Miller 
LH. Domain III of Plasmodium falciparum 
apical membrane antigen 1 binds to the 
erythrocyte membrane protein Kx. Proceedings 
of the National Academy of Sciences. 
2005;102(15):5552-7. 
14. Anders RF, Adda CG, Foley M, Norton RS. 
Recombinant protein vaccines against the 
asexual blood-stages of Plasmodium falciparum. 
Human vaccines. 2010;6(1):39-53. 
15. Jahangiri F, Jalallou N, Ebrahimi M. Analysis 
of Apical Membrane Antigen (AMA)-1 
characteristics using bioinformatics tools in 
order to vaccine design against Plasmodium 
vivax. Infection, Genetics and Evolution. 
2019;71:224-31. 
16. Mirahmadi H, Rafee M, Zaman J, Mehravaran 
A, Shafiei R. Mutational analysis of 
Plasmodium vivax dhfr gene among cases in 
south east of Iran. Jundishapur Journal of 
Microbiology. 2017;10(9). 
           Ethiop J Health Sci.                               Vol. 30, No. 4                                        July 2020 
 
 




17. Thera MA, Doumbo OK, Coulibaly D, Laurens 
MB, Ouattara A, Kone AK, et al. A field trial to 
assess a blood-stage malaria vaccine. New 
England Journal of Medicine. 
2011;365(11):1004-13. 
18. Ouattara A, Mu J, Takala-Harrison S, Saye R, 
Sagara I, Dicko A, et al. Lack of allele-specific 
efficacy of a bivalent AMA1 malaria vaccine. 
Malaria journal. 2010;9(1):175. 
19. Dutta S, Dlugosz LS, Drew DR, Ge X, 
Ababacar D, Rovira YI, et al. Overcoming 
antigenic diversity by enhancing the 
immunogenicity of conserved epitopes on the 
malaria vaccine candidate apical membrane 
antigen-1. PLoS pathogens. 
2013;9(12):e1003840. 
20. Miura K, Herrera R, Diouf A, Zhou H, Mu J, 
Hu Z, et al. Overcoming allelic-specificity by 
immunization with 5-allelic forms of 
Plasmodium falciparum Apical Membrane 
Antigen 1. Infection and immunity. 2013:IAI. 
01414-12. 
21. Neafsey DE, Galinsky K, Jiang RH, Young L, 
Sykes SM, Saif S, et al. The malaria parasite 
Plasmodium vivax exhibits greater genetic 
diversity than Plasmodium falciparum. Nature 
genetics. 2012;44(9):1046. 
22. Arévalo-Herrera M, Chitnis C, Herrera S. 
Current status of Plasmodium vivax vaccine. 
Human vaccines. 2010;6(1):124-32. 
23. Chenet SM, Pacheco MA, Bacon DJ, Collins 
WE, Barnwell JW, Escalante AA. The evolution 
and diversity of a low complexity vaccine 
candidate, merozoite surface protein 9 (MSP-9), 
in Plasmodium vivax and closely related 
species. Infection, Genetics and Evolution. 
2013;20:239-48. 
24. Haghi AM, Nateghpour M, Edrissian G, 
Sepehrizadeh Z, Mohebali M, Khoramizade M, 
et al. Sequence analysis of different domains of 
Plasmodium vivax apical membrane antigen 
(pvama-1 gene) locus in iran. Iranian Journal of 
Parasitology. 2012;7(1):26. 
25.  Rouhani S, Raeghi S, Mirahmadi H, Fasihi MF, 
Haghighi A, Spotin A. Identification of Fasciola 
spp. in the east of Iran, based on the 
spermatogenesis and nuclear ribosomal DNA 
(ITS1) and mitochondrial (ND1) genes. 
Archives of Clinical Infectious Diseases. 2017; 
12 (2): e57283. sciences: PJBS. 
2017;20(4):204-9. 
26. Woday A, Mohammed A, Gebre A, Urmale K. 
Prevalence and Associated Factors of Malaria 
among Febrile Children in Afar Region, 
Ethiopia: A Health Facility Based Study. 
Ethiopian journal of health sciences. 
2019;29(5): 613-622. 
27. Rajesh V, Elamaran M, Vidya S, Gowrishankar 
M, Kochar D, Das A. Plasmodium vivax: 
genetic diversity of the apical membrane 
antigen-1 (AMA-1) in isolates from India. 
Experimental parasitology. 2007;116(3):252-6. 
28. Valizadeh M, Haghpanah B, Badirzadeh A, 
Roointan E, Fallahi S, Raeghi  S. Immunization 
of sheep against Echinococcus granulosus with 
protoscolex tegumental surface antigens. 
Veterinary World. Vet World. 2017;10(8):854.  
29. Nedaei F, Noormohammadi Z, Naddaf SR, 
Mohammadi S, Rastaghi ARE. Analysis of 
Plasmodium vivax Apical Membrane Antigen-1 
(PvAMA-1) Haplotypes among Iranian Isolates. 
International journal of molecular and cellular 
medicine. 2017;6(4):222. 
30. Igonet S, Vulliez-Le Normand B, Faure G, 
Riottot M-M, Kocken CH, Thomas AW, et al. 
Cross-reactivity studies of an anti-Plasmodium 
vivax apical membrane antigen 1 monoclonal 
antibody: binding and structural 
characterisation. Journal of molecular biology. 
2007;366(5):1523-37. 
31. Triglia T, Healer J, Caruana SR, Hodder AN, 
Anders RF, Crabb BS, et al. Apical membrane 
antigen 1 plays a central role in erythrocyte 
invasion by Plasmodium species. Molecular 
microbiology. 2000;38(4):706-18. 
32. Rodrigues MHC, Rodrigues KM, Oliveira TR, 
Cômodo AN, Rodrigues MM, Kocken CH, et 
al. Antibody response of naturally infected 
individuals to recombinant Plasmodium vivax 
apical membrane antigen-1. International 
journal for parasitology. 2005;35(2):185-92. 
33. Lopez AC, Ortiz A, Coello J, Sosa-Ochoa W, 
Torres REM, Banegas EI, et al. Genetic 
diversity of Plasmodium vivax and Plasmodium 
falciparum in Honduras. Malaria journal. 
2012;11(1):391. 
34. Dias S, Somarathna M, Manamperi A, Escalante 
AA, Gunasekera AM, Udagama PV. Evaluation 
of the genetic diversity of domain II of 
Plasmodium vivax Apical Membrane Antigen 1 
(PvAMA-1) and the ensuing strain-specific 
immune responses in patients from Sri Lanka. 
Vaccine. 2011;29(43):7491-504. 
35. Kang J-M, Lee J, Cho P-Y, Moon S-U, Ju H-L, 
Ahn SK, et al. Population genetic structure and 
natural selection of apical membrane antigen-1 
in Plasmodium vivax Korean isolates. Malaria 
journal. 2015;14(1):455. 
 
